Stephen P. Fortmann, MD

Clinical Focus

• Cardiology (Heart), Preventive
• Internal Medicine
• Primary Prevention

Administrative Appointments

• Director, Stanford Prevention Research Center (1998 - present)

Honors and Awards

• Member, Institute of Medicine of the National Academies (2005)
• Fellow, Society for Behavioral Medicine (1983)
• Fellow, American Heart Association (1984)
• Fellow, American College of Physicians (1987)
• Fellow, American College of Epidemiology (1988)

Professional Education

Postdoctoral Advisees

Dipanjan Banerjee, Matthew Buman, Mindy Dopler Nelson, Eric Hekler, Valarie Jernigan, Marina Martin, Susan Moore, Stacy Sims

Graduate & Fellowship Program Affiliations

• Epidemiology
• Medicine

Community & International Work

• MONICA (Multinational MONItoring of trends and determinants in CArdiovascular disease) Project 

Web Site Links

• Stanford Prevention Research Center

Industry Relationships

Stanford is committed to ethical and transparent interactions with our industry partners. It is our policy to disclose payments of $5,000 or more, equity valued at $5,000 or more in a publicly traded company, or any equity in a privately held company, to physicians and scientists employed by Stanford University from companies or other commercial entities with which they interact as part of their professional activities. View Full Information

Research Interests

ACTIVE STUDIES

1 RO1 DA017441 (PI Killen); 9/30/03–6/30/08; NIH/NIDA
Behavioral Maintenance Treatment for Smoking Cessation
To examine the effectiveness of a multi-factor maintenance treatment strategy in promoting longer-term smoking abstinence.
Role: Co-PI

2 R01 CA67850 (Fortmann); 08/02/05–4/30/10; NIH/NCI
Impact of Retail Tobacco Advertising on Youth Smoking
This project is a longitudinal survey to determine effects of exposure to retail tobacco advertising on smoking initiation.

5 R01 DA017457 (Killen);09/30/03-7/31/09; NIH/NIDA
Selegeline Patch for Treatment of Nicotine Dependence
To conduct the first randomized controlled trial of the efficacy of selegiline patch for the treatment of nicotine dependence.
Role: Co-PI, Medical Director

1 R01 HL87647-01 (PI Quertermous); 09/30/06–07/31/09; NIH
Whole Genome Association for Early Coronary Artery Disease and Related Phenotypes
Among the Atherosclerotic Disease, Vascular Function, and Genetic Epidemiology (ADVANCE) cohorts that enrolled cases of coronary disease and disease-free controls across a broad age spectrum, we propose to conduct a whole genome association study on 1,040 subjects followed by a second stage of focused genotyping on a separate sample of 2,093 subjects, as well as replication of the most significant findings with collaborating external investigators.
Role: Investigator

2 T32 HL07034 Fortmann (PI); 08/1/06 –07/31/11; NIH/NHLBI
Cardiovascular Disease Prevention Training Program
This Training Program is an institutional National Research Service Award with 8 postdoctoral positions; it provides training for behavioral scientists and physicians in interdisciplinary CVD prevention research.

17RT-0152 (Henriksen); 07/01/08-06/30/11;Tobacco-Related Disease Research Program (TRDRP)
Association of Outlet Density with Smoking and Pack Price
This study seeks to understand whether the concentration...

Publications

• Insulin resistance independently predicts the progression of coronary artery calcification. Lee KK, Fortmann SP, Fair JM, Iribarren C, Rubin GD, Varady A, Go AS, Quertermous T, Hlatky MA. Am Heart J. 2009; 157 (5): 939-45
• Distribution of Asymmetric Dimethylarginine among 980 Healthy, Older Adults of Different Ethnicities. Sydow K, Fortmann SP, Fair JM, Varady A, Hlatky MA, Go AS, Iribarren C, Tsao PS. Clin Chem. 2009
• Susceptibility locus for clinical and subclinical coronary artery disease at chromosome 9p21 in the multi-ethnic ADVANCE study. Assimes TL, Knowles JW, Basu A, Iribarren C, Southwick A, Tang H, Absher D, Li J, Fair JM, Rubin GD, Sidney S, Fortmann SP, Go AS, Hlatky MA, Myers RM, Risch N, Quertermous T. Hum Mol Genet. 2008; 17 (15): 2320-8
• Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Assimes TL, Knowles JW, Priest JR, Basu A, Volcik KA, Southwick A, Tabor HK, Hartiala J, Allayee H, Grove ML, Tabibiazar R, Sidney S, Fortmann SP, Go A, Hlatky M, Iribarren C, Boerwinkle E, Myers R, Risch N, Quertermous T. Hum Genet. 2008; 123 (4): 399-408
• Receptivity to alcohol marketing predicts initiation of alcohol use. Henriksen L, Feighery EC, Schleicher NC, Fortmann SP. J Adolesc Health. 2008; 42 (1): 28-35